The FDA's decision to grant priority review to Syndax Pharmaceuticals' Revumenib is a significant positive development for the company. This status not only highlights the potential of Revumenib as a treatment option but also accelerates the review process, potentially leading to an earlier market entry. Given the specific focus on relapsed/refractory KMT2Ar acute leukemia, a condition with limited treatment options, this news could significantly impact Syndax's market position and investor sentiment in the short term.